JD vs POM
JD.com, Inc. and Pomdoctor Ltd., side by side — 3 fiscal years reported in CNY, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | JD | POM |
|---|---|---|
| Revenue | CNY 1.3T | CNY 399.9M |
| Net income | CNY 23.1B | CNY -130.9M |
| Gross margin | 16.0% | 13.1% |
| Net margin | 1.8% | −32.7% |
| Return on equity | — | — |
| Diluted EPS | CNY 6.45 | −CNY 21.96 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | CNY 11.2B | CNY -149.5M |
| Equity | CNY 225.0B | CNY -454.0M |
| Net debt / equity | −0.41× | — |
| Current ratio | 1.22× | 0.48× |
| Revenue CAGR 5y | 11.9% | — |
| Profit CAGR 5y | −14.1% | — |
JD bills 3273.4× the revenue of POM, and POM closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Revenue by year
3 years side by side
| Fiscal year | JD | POM |
|---|---|---|
| FY2025 | CNY 1.3T | CNY 399.9M |
| FY2024 | CNY 1.2T | CNY 342.6M |
| FY2023 | CNY 1.1T | CNY 304.9M |
Net income by year
Bottom line
| Fiscal year | JD | POM |
|---|---|---|
| FY2025 | CNY 23.1B | CNY -130.9M |
| FY2024 | CNY 44.7B | CNY -37.4M |
| FY2023 | CNY 23.3B | CNY -36.9M |
More in this industry